Thanks to the cannabis market’s burgeoning path, new listings are appearing regularly.
The emerging NEO Exchange has opened itself up to listing more marijuana stocks since it elected not to block companies with operating assets in the US.
“Clearly we are moving now in a period where there was a lot of focus on US marijuana firms,” Jos Schmitt, president and CEO of the NEO, previously told the Investing News Network (INN), “There’s a lot of interest in that space.”
The appeal of the NEO has reached a variety of cannabis companies looking to raise capital in Canada. Investors are now seeing more options for the Toronto-based exchange.
Here INN offers investors a growing list of active cannabis stocks found on the NEO.
Ayr Strategies (NEO:AYR.A,OTCQX:AYRSF)
Ayr Strategies reached the NEO as a special purpose acquisition corporation (SPAC). Once it became public, it started operating as a vertically integrated multi-state operator (MSO) in the US cannabis sector with assets in Nevada and Massachusetts.
Columbia Care (NEO:CCHW,OTC Pink:COLXF)
Columbia Care is an MSO that is present in 15 jurisdictions in the US cannabis market, including marijuana shops and growing facilities.
Halo Labs (NEO:HALO,OTCQX:AGEEF)
This firm offers a play into the cannabis extraction market with production of cannabis oils and concentrates and operations in California, Nevada and Oregon.
Jushi Holdings (NEO:JUSH.B)
Jushi Holdings reached the NEO as an MSO focused on cannabis and hemp-derived assets in the US market. It is looking to expand its branded product line across legal markets.
Maple Leaf Green World (NEO:MGW,OTCQX:MGWFF)
Maple Leaf Green World is a cannabis company with interests in the Canadian and US markets. The firm has growing operations in Canada and a focus on the production and export of cannabis oil.
Mercer Park Brand Acquisition (NEO:BRND.U)
This company is a SPAC looking for acquisitions in the cannabis business or deals adjacent to the industry. The company has not limited itself to only cannabis acquisitions.
Subversive Capital Acquisition (NEO:SVC.UN.U)
Subversive Capital Acquisition (SCAC) is a SPAC looking for opportunities in the overall cannabis market. To date, SCAC’s SPAC listing is the largest on the NEO.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.